LGALS9B

Across TCGA pan-cancer cohorts, LGALS9B RNA is linked to patient survival in 28 of 34 cancer types, making it the most broadly survival-associated LGALS9B data layer compared with 4 for mutation status.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher LGALS9B RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated LGALS9B expression acts as an unfavorable survival marker, although some lineages such as MESO and SCLC show a favorable association.

CHOL, MESO, and LUAD are the cancer types where LGALS9B RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	DFS	Quartile	All	0.088	0.618	<.001	72	view →
MESO	DFS	Tertile	All	0.527	0.259	<.001	57	view →
LUAD	DFS	Median	III,IV	0.171	0.409	<.001	50	view →
LGG	DFS	Median	All	0.650	0.793	<.001	42	view →
SCLC	OS	Tertile	All	0.707	0.344	<.001	38	view →
LAML	DFS	Tertile	All	0.381	0.747	.001	36	view →
COAD	DFS	Quartile	II,III,IV	0.805	0.545	.005	29	view →
UVM	OS	Tertile	III,IV	0.428	0.876	.015	21	view →
HNSC	DFS	Tertile	IV	0.334	0.662	.001	18	view →
LIHC	DFS	Median	All	0.506	0.366	.001	14	view →
LUSC	DFS	Median	All	0.446	0.351	.021	12	view →
STAD	DFS	Tertile	IV	0.815	0.359	.028	10	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 28 lineages.

LGALS9B–CHOL (DFS)

Open the CHOL breakdown →